tessathe | Tessa Therapeutics – Cancer Immunotherapy Treatments

What are you looking for?

- home-featured
- news-pressrelease
Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting

Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue Reading
- Singapore - Finance
Manager, Finance and Compliance

Excerpt Publication 2 Sample Excerpt
Continue Reading
- Singapore - Clinical Operations and Data Management
Associate Manager, Clinical Projects

Excerpt Publication 2 Sample Excerpt
Continue Reading
- Singapore - Quality
Manager/Lead, Quality Control (Bioanalytical)

Excerpt Publication 2 Sample Excerpt
Continue Reading
- Singapore - Manufacturing
Biotechnologist Lead

Excerpt Publication 2 Sample Excerpt
Continue Reading
- US - Human Resource
Associate Director/Director, Human Resource (New Jersey)

Excerpt Publication 2 Sample Excerpt
Continue Reading
- US - Clinical Operations
Senior Manager, Clinical Documentation (New Jersey)

Excerpt Publication 2 Sample Excerpt
Continue Reading
- Singapore - Strategy & Program Management
Senior Manager, Strategy & Program Management

Excerpt Publication 2 Sample Excerpt
Continue Reading